Clinical Trial Update: Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE) [Phase 3]

View source ↗

Summary

Phase 3 trial update for dupilumab in adults and adolescents with eosinophilic esophagitis has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Eosinophilic Esophagitis

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Eosinophilic Esophagitis | Phase 3 | Status: COMPLETED | Results posted: 2022-12-28